

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

| H H H H H | |
|-------------------|--------------|
| 16602-1 | |
| 1 1- | OMB APPROVAL |

OMB Number: 3235-0076 Expires: April 30, 2008 Estimated average burden hours per response: 16.00

| SEC USE ON | ILY |
|------------|--------|
| Prefix | Serial |
| DATE RECEI | VED |

| Name of Offering (check if this is an amendm QuatRx Pharmaceuticals Company Series E Pres | | | | | | | |
|---|--|----------------------|---|------------|-----------------|-------------|---------|
| Filing Under (Check box(es) that apply): | Rule 504 | Rule 505 | ⊠Rul | e 506 | Section 4 | • • | ULOE |
| Type of Filing: | □New | Filing | | | ⊠Amendment | | |
| | A. BASIC IDE | NTIFICATION D | ATA | | | | |
| 1. Enter the information requested about the is: | suer | | | | | | |
| Name of Issuer (☐check if this is an amendmen QuatRx Pharmaceuticals Company | t and name has chang | ed, and indicate cha | ange.) | | " . | | |
| Address of Executive Offices | (Number and Street, | City, State, Zip Co | ode) | | one Number (Inc | luding Area | Code) |
| 777 East Eisenhower Parkway, Suite 100, Ann A | Arbor, MI 48108 | | | 734-91 | 3-9900 | | |
| Address of Principal Business Operations | (Number and Street, | | ode) BOCE | | one Number (Inc | luding Area | Code) |
| Brief Description of Business | | 72 | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | - | | |
| Development and clinical testing of pharmaceuti | cal compounds | <u> </u> | JUN 25 | 2007 | | | |
| Type ⊠corporation | limited partnersh | ip, already formed | THOMS | :ON | other (please | specify) | |
| business trust | limited partnersh | ip, to be formed | FINANC | MAL | | | |
| | | <u>Month</u> | Year | <i>///</i> | | | |
| Actual or Estimated Date of Incorporation or Or | ganization: | November | 2000 | | ⊠Actual | ☐ Es | timated |
| Jurisdiction of Incorporation or Organization: | (Enter two-letter U.S CN for Canada, FN | | | or State: | DE | | |
| | | | | | | | |

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C 77d(6).

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

<u>Copies Required</u>: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

A. BASIC IDENTIFICATION DATA

- 2. Enter the information requested for the following:
 - Each promoter of the issuer, if the issuer has been organized within the past five years;
 - Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;

| Each executive officer | and director of corporate issuers and | of corporate general and managing partners of pa | artnership issuers; and |
|--|--|--|---------------------------------------|
| Each general and mana | aging partner of partnership issuers. | | |
| Check Box(es) | Promoter | Beneficial Owner | 図Executive Officer |
| that Apply: | ⊠Director | General and/or Managing Partner | |
| Full Name (Last name first, if i | | | · · · · · · · · · · · · · · · · · · · |
| Zerbe, Robert L. | • | | |
| Business or Residence Address | s (Number and Street, City, State, Zip | | |
| c/o QuatRx Pharmaceuticals Co | ompany, 777 East Eisenhower Parkwa | ay, Suite 100, Ann Arbor, MI 48108 | |
| Check Box(es) | Promoter | Beneficial Owner | ⊠Executive Officer |
| that Apply: | Director | General and/or Managing Partner | |
| Full Name (Last name first, if i | ndividual) | | |
| Onn, Gary | | | |
| | s (Number and Street, City, State, Zip | | |
| | ompany, 777 East Eisenhower Parkwa | | |
| Check Box(es) | Promoter | Beneficial Owner | ☑Executive Officer |
| that Apply: | Director | General and/or Managing Partner | |
| Full Name (Last name first, if i | ndividual) | | |
| Dombey, Stuart L. | | | |
| | s (Number and Street, City, State, Zip | | |
| | ompany, 777 East Eisenhower Parkwa | | |
| Check Box(es) | Promoter | Beneficial Owner | ☑Executive Officer |
| that Apply: | Director | General and/or Managing Partner | |
| Full Name (Last name first, if i | ndividual) | | |
| Nicholas, Christopher I. | | | <u> </u> |
| | s (Number and Street, City, State, Zip | | |
| | ompany, 777 East Eisenhower Parkwa | | |
| Check Box(es) | Promoter | Beneficial Owner | |
| that Apply: | Director | General and/or Managing Partner | |
| Full Name (Last name first, if i | ndividual) | | |
| Hanley, Rochelle | 0. 1 10 0. 0. 0. 0. | | |
| | Number and Street, City, State, Zip | | |
| | ompany, 777 East Eisenhower Parkwa | Beneficial Owner | Mr. Com |
| Check Box(es) | Promoter | | ⊠Executive Officer |
| that Apply: | Director | General and/or Managing Partner | · |
| Full Name (Last name first, if i | ndividual) | | |
| Brinza, Jeffery | (Number and Street, City, State, Zip | Code | |
| | ompany, 777 East Eisenhower Parkwa | | |
| Check Box(es) | Promoter | Beneficial Owner | Executive Officer |
| ` ' | ⊠Director | General and/or Managing Partner | |
| that Apply: Full Name (Last name first, if i | | General and/or Managing Partner | |
| Fox, Richard P. | narviduai) | | |
| | (Number and Street, City, State, Zip | Code) | - ···. |
| P.O. Box 558, Mercer Island, V | | | |
| Check Box(es) | Promoter | Beneficial Owner | Executive Officer |
| that Apply: | ⊠Director | General and/or Managing Partner | |
| Full Name (Last name first, if it | | | |
| Simon, Nicholas, III | | | |
| | (Number and Street, City, State, Zip | Code) | |
| | ., 111 Huntington Ave., 31st Floor, Bo | | |

| i , | | | |
|--|---|---------------------------------------|--------------------|
| Check Box(es) | ☐Promoter | Beneficial Owner | Executive Officer |
| that Apply: | ⊠Director | General and/or Managing Partner | |
| Full Name (Last name first, i | f individual) | | |
| Heron, Patrick | - | | |
| Business or Residence Addre | ess (Number and Street, City, State, Zin Street, Suite 3300, Seattle, WA 9810 | | |
| Check Box(es) | Promoter | Beneficial Owner | Executive Officer |
| that Apply: | ⊠Director | General and/or Managing Partner | • |
| Full Name (Last name first, i | f individual) | | |
| Wantanabe, August | • | | |
| | ess (Number and Street, City, State, Zi | p Code) | |
| 10666 Winterwood, Carmel, | IN 46032 | | |
| Check Box(es) | □ Promoter | Beneficial Owner | ☐Executive Officer |
| that Apply: | ⊠Director | General and/or Managing Partner | |
| Full Name (Last name first, i | f individual) | | |
| Ehrlich, Christopher | | · · · · · · · · · · · · · · · · · · · | |
| | ess (Number and Street, City, State, Zi | | |
| c/o InterWest Partners, 2710 | Sand Hill Rd., Second Floor, Menlo I | | |
| Check Box(es) | Promoter | Beneficial Owner | Executive Officer |
| that Apply: | ☑ Director | General and/or Managing Partner | |
| Full Name (Last name first, i | f individual) | | |
| Castelein, Caley | | | |
| | ess (Number and Street, City, State, Zi | | |
| | re Ventures, One Montgomery St., Sai | | |
| Check Box(es) | Promoter | Beneficial Owner | Executive Officer |
| that Apply: | ☑ Director | General and/or Managing Partner | |
| Full Name (Last name first, i | f individual) | | |
| Moller, Christopher | | | |
| | ess (Number and Street, City, State, Zi | | |
| | ng, 435 Devon Park Dr., Wayne, PA | | |
| Check Box(es) | Promoter | ☐ Beneficial Owner | ☐Executive Officer |
| that Apply: | ☑ Director | General and/or Managing Partner | |
| Full Name (Last name first, i | f individual) | | |
| Wiklund, Anders | | | |
| Business or Residence Addre 928 Sunset Ridge, Bridgewat | ess (Number and Street, City, State, Ziter, NJ 08807 | p Code) | |
| Check Box(es) | Promoter | ☐ Beneficial Owner | Executive Officer |
| that Apply: | ☑ Director | General and/or Managing Partner | |
| Full Name (Last name first, i | f individual) | | |
| Hove, Anders | • | | |
| Business or Residence Addre | ess (Number and Street, City, State, Zi | p Code) | |
| 30 Rockefeller Plaza, Suite 5 | 508, New York, NY 10112 | | |
| Check Box(es) | Promoter | ⊠ Beneficial Owner | Executive Officer |
| that Apply: | Director | General and/or Managing Partner | |
| Full Name (Last name first, i | f individual) | | |
| Frazier Healthcare III, L.P. | .1 | | |
| | ess (Number and Street, City, State, Zi | p Code) | |
| 601 Union Street, Suite 3300 | 0, Seattle, WA 98101 | | |
| Check Box(es) | Promoter | ☑ Beneficial Owner | Executive Officer |
| that Apply: | Director | General and/or Managing Partner | |
| Full Name (Last name first, i | f individual) | | |
| TL Ventures V L.P. ² | | | • |
| | ess (Number and Street, City, State, Zi | p Code) | |
| 700 Building, 435 Devon Par | rk Dr., Wayne, PA 19087-1990 | | |
| | | | |

¹ Securities are owned by Frazier Healthcare III, L.P. and Frazier Affiliates III, L.P. ² Securities are owned by TL Ventures V L.P. and TL Ventures V Interfund, L.P. Page 3 of 12

| Check Box(es) | Promoter | ☑ Beneficial Owner | ☐ Executive Officer |
|---|---|----------------------------------|---------------------|
| that Apply: | ☐ Director | General and/or Managing Partner | |
| Full Name (Last name first, if ir | ndividual) | - | |
| MPM Bio Ventures III-QP, L | .P. ³ | | |
| Business or Residence Address | (Number and Street, City, State, Zip | Code) | |
| 111 Huntington Ave., 31st Floor | r, Boston, MA 02199 | | |
| Check Box(es) | Promoter | ⊠ Beneficial Owner | ☐Executive Officer |
| that Apply: | Director | General and/or Managing Partner | - |
| Full Name (Last name first, if in | | | |
| InterWest Partners VIII, L.P. | | | |
| Business or Residence Address 2710 Sand Hill Rd., Second Flo | (Number and Street, City, State, Zip oor, Menlo Park, CA 94025 | p Code) | |
| Check Box(es) | Promoter | ☑ Beneficial Owner | Executive Officer |
| that Apply: | Director | General and/or Managing Partner | _ |
| Full Name (Last name first, if in | | 0 0 | |
| Thomas Weisel Healthcare Ve | | | |
| | (Number and Street, City, State, Zip | Code) | |
| One Montgomery St., San Francisco | | | |
| Check Box(es) | Promoter | ☑ Beneficial Owner | Executive Officer |
| that Apply: | Director | General and/or Managing Partner | |
| Full Name (Last name first, if it | ndividual) | ···· | |
| Bio Fund Ventures II Jatkosij | | | |
| Business or Residence Address | (Number and Street, City, State, Zip | Code) | |
| Mikonkatu 4, 3rd Floor, PO Box | (164, 00101 Helsinki, Finland | | |
| Check Box(es) | Promoter | ☑ Beneficial Owner | Executive Officer |
| that Apply: | Director | General and/or Managing Partner | |
| Full Name (Last name first, if ir | ndividual) | | |
| Biomedical Venture III Ltd. (1 | | | |
| | (Number and Street, City, State, Zip | | |
| BankInvest Group, Sundkrogsg | ade 7, P.O. Box 2672, DK-2100 Co | | |
| Check Box(es) | Promoter | ☑ Beneficial Owner | ☐Executive Officer |
| that Apply: | Director | ☐General and/or Managing Partner | |
| Full Name (Last name first, if ir | ndividual) | | |
| H&B Capital LP | | | |
| | (Number and Street, City, State, Zip | | |
| | <u>, Humlegardsgatan 14, SE-144 46 S</u> | | |
| Check Box(es) | Promoter | □ Beneficial Owner | Executive Officer |
| that Apply: | Director | General and/or Managing Partner | |
| Full Name (Last name first, if in | | | |
| SITRA, The Finnish Innovation | | | |
| | (Number and Street, City, State, Zip | Code) | |
| Itamerentori 2, P.O. Box 160, F | | T70 6110 | |
| Check Box(es) | Promoter | ⊠ Beneficial Owner | Executive Officer |
| that Apply: | Director | General and/or Managing Partner | |
| Full Name (Last name first, if in | idividual) | | |
| Venrock Associates V, L.P. ⁷ | A) 1 10 | 0.17 | |
| | (Number and Street, City, State, Zip | o Code) | |
| 30 Rockefeller Plaza, Suite 550 | o, NEW TUIK, NT TUITZ | | |

³ Securities are owned by MPM Bio Ventures III, LP, MPM Bio Ventures III-QP, LP, MPM Bio Ventures III Parallel Fund, LP, MPM Bio Ventures III GmbH &Co. Beteiligungs KG, MPM Asset Management Investors 2003 BVIII LLC, and MPM Bioventures Strategic Fund, L.P.

⁴ Securities are owned by InterWest Partners VIII, L.P., InterWest Investors VIII, L.P., and InterWest Investors Q VIII,

⁵ Securities are owned by Bio Fund Ventures I Ky, Bio Fund Ventures II Jatkosijoitusrahasto Ky, and Bio Fund Ventures

⁶ Securities are owned by Biomedical Venture III Ltd. (P/S) and k/s Biomedical Venture Annex III.

⁷ Securities are owned by Venrock Associates V, L.P. and Venrock Entrepreneurs Fund V, L.P.

| • | | | |
|-------------------------|----------------------------------|---------------------------------|---------------------|
| Check Box(es) | Promoter | ☑ Beneficial Owner | ☐ Executive Officer |
| that Apply: | Director | General and/or Managing Partner | |
| Full Name (Last name | first, if individual) | | |
| T. Rowe Price Health | Sciences Fund, Inc. | | |
| Business or Residence | Address (Number and Street, City | , State, Zip Code) | |
| 100 East Pratt Street E | taltimore MD 21202 | | |

| | | | | | В. І | NFORMA | TION ABO | UT OFFER | ING | | | | |
|-------------|-------------|--------------------|------------------------------|--|-------------------------------|--------------------------------|---------------|-----------------------------------|-------------------------------|-------------------------------|---------------------------------|-----------------------------|--------------|
| 1. | Has the is | ssuer sol | ld, or does | the issuer in | | to non-accre o in Append | | | | | Yes 🗌 | No ⊠ | |
| 2. | What is th | ne minir | num invest | ment that wi | ll be accepte | ed from any | individual?. | | ••••• | ************* | \$ <u>NA</u> | - | |
| 3. | Does the | offering | permit joi | nt ownership | of a single | unit? | | | | | Yes ⊠ | No 🗌 | |
| | remunerat | tion for broker | solicitation or dealer re | sted for each of purchase egistered wit ciated persor | ers in connec th the SEC a | ction with sa .nd/or with a | les of securi | ities in the o tes, list the n | ffering. If a ame of the b | person to be proker or dea | e listed is an aler. If more | associated per than five (5 | |
| Full N/A | | ast nam | e first, if in | dividual) | | | | | | | | | |
| | | | . 4 3 3 | Ol | 1 Cause Cia | . Cara 7: | C-1-) | | | | | | |
| Bus: | iness or K | esidenc | e Address | (Number and | Street, City | y, State, Zip | Code) | | | | | | |
| Nan | ne of Asso | ociated I | Broker or D | Dealer | • | | | | | · | | | |
| | | | | las Solicited lividual State | | | chasers | | | | All State | s 🔲 | |
| [AL |] [A | AK] | [AZ] | [AR] | [CA] | [CO] | [CT] | [DE] | [DC] | [FL] | [GA] | [HI] | [ID] |
| (IL) | - | N] | [IA] | [KS] | [KY] | [LA] | [ME] | [MD] | [MA] | [MI] | [MN] | [MS] | [MO] |
| [M] | | NE] | [NV] | [NH] | [NJ] | [NM] | [NY] | [NC] | [ND] | [OH] | [OK] | [OR] | [PA] |
| [RI] | | SC] | [SD] e first, if in | [TN] | [TX] | [UT] | [VT] | [VA] | [VA] | [WV] | [WI] | [WY] | [PR] |
| | - Tunne (D | ast main | e mot, n m | arriadar) | | | | | | | | | |
| Bus | iness or R | esidenc | e Address | (Number and | l Street, City | y, State, Zip | Code) | | | | | | |
| Nan | ne of Asso | ociated I | Broker or D | Dealer | | | | | | | | | |
| | | | | las Solicited | | | | | | | | | |
| | | | | lividual State | | | | | | | | | |
| [AL | | AK] | [AZ] | [AR] | [CA] | [CO] | [CT] | [DE] | [DC] | (FL) | [GA] | [HI] | [ID] |
| [IL] [M] | _ | N] NE] | [IA] [NV] | [KS] | [KY] [NJ] | [LA] [NM] | [ME] [NY] | [MD] | (MA) | (MI) | [MN] | [MS] | [MO] |
| [RI] | - | SC] | [SD] | [NH] [TN] | [TX] | [UT] | [VT] | [NC] [VA] | [ND] [VA] | (OH) [WV] | [OK] [WI] | [OR] [WY] | (PA] [PR] |
| | | ast nam | e first, if in | | | | | | | | | | |
| Bus | iness or R | esidenc | e Address (| (Number and | Street, City | y, State, Zip | Code) | | | | | | |
| Nan | ne of Asso | ociated I | Broker or E |)ealer | | | | | | | | | |
| State | es in Whi | ch Perso | on Listed H | las Solicited | or Intends t | o Solicit Put | chasers | | | | | | |
| • | | | | lividual State | - | | | | | | | _ | |
| [AL | | AK] | [AZ] | [AR] | [CA] | [CO] | [CT] | [DE] | [DC] | [FL] | [GA] | [HI] | [ID] |
| [IL] | _ | N] | [IA] | [KS] | [KY] | [LA] | [ME] | [MD] | [MA] | [MI] | [MN] | [MS] | [MO] |
| [MT | | NE] SC] | [NV] [SD] | [NH] [TN] | [NJ] [TX] | [NM] [UT] | [NY] [VT] | [NC] [VA] | [ND] (VA] | [OH] [WV] | [OK] [WI] | [OR] [WY] | [PA] [PR] |

| | C. OFFERING PRICE, NUMBER OF INVESTORS, EXPE | NSES AND USE OF PROCI | EEDS |
|----|---|---|--------------------------------------|
| 1. | Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \(\square\$\) and indicate in the columns below the amounts of the securities offering for exchange and already exchanged. | | |
| | Type of Security | Aggregate Offering Price | Amount Already Sold |
| | Debt | \$ | \$ <u>-0-</u> |
| | Equity | \$ <u>32,757,043.88</u> | \$ <u>32,757,043.88</u> |
| | ☐ Common ☑ Preferred | \$\sigma_{\sigma\in\sigma_{\sigma_{\sigma_{\sigma_{\sigma_{\sigma_{\sigma_{\sigma_{\initin\sigma_{\sigma_{\initin\sigma_{\initin\sigma_{\sigma_\sigma_\initin\simi_{\simi_{\initin\sigma_{\initin\sigma_\initin\limi\limi_\initin\simi_\initin\simi_\initin\simi_\initin\simi_\initin\simi_\initin\simi_\initin\simi_\inii\limi\iii\limi\limi\iii\limi\iii\limi\iii\limi\limi\iiii\limi\iii\limi\iii\ii | V <u>021,07,07000</u> |
| | Convertible Securities (including warrants) | \$ | \$ -0- |
| | Partnership Interests | \$ | \$ |
| | Other (Specify) | \$ | \$ |
| | | | · |
| | Total | \$ <u>32,757,043.88</u> | \$ <u>32,757,043.88</u> |
| | Answer also in Appendix, Column 3, if filing under ULOE. | | |
| 2. | Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero." | | |
| | | Number Investors | Aggregate Dollar Amount Of Purchases |
| | A 1971 11 - 2 | | |
| | Accredited Investors | 30 | \$32,757,043.88 |
| | Non-accredited Investors | <u>-0-</u> -0- | \$ <u>-0-</u> -0- |
| | Total (for filings under Rule 504 only) | 0- | -U- |
| 3. | If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1. | | |
| | Type of Offering | Type of Security | Dollar Amount Sold |
| | Rule 505 | -0- | \$0- |
| | Regulation A | -0- | \$ -0- |
| | Rule 504 | -0- | \$ -0- |
| | Total | -0- | \$ |
| 4. | a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate. | | |
| | Transfer Agent's Fees | | \$ -0- |
| | Printing and Engraving Costs | | \$ |
| | Legal Fees | <u></u> | \$ 185,000 |
| | Accounting Fees | | \$ <u>-0-</u> |
| | Engineering Fees | | \$ <u>-0-</u> |
| | Sales Commissions (specify finders' fees separately) | <u> </u> | \$ <u>1,030,000</u> |
| | Other Expenses (Identify) Filing fees | $oldsymbol{\boxtimes}$ | \$ |
| | Total | oxtimes | \$ <u>1,217,400</u> |
| | b. Enter the difference between the aggregate offering price given in response to | | |
| | Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer" | | \$ <u>31,539,643.88</u> |
| | American completion and and and and and and and and and an | | |

| C. OFFERING PRICE, NUMBER OF INVESTO | RS, EXPENSES AND USE OF PRO | OCEEDS |
|--|---|-----------------------------------|
| 5. Indicate below the amount of the adjusted gross proceeds to the issuer use proposed to be used for each of the purposes shown. If the amount for an purpose is not known, furnish an estimate and check the box to the left of estimate. The total of the payments listed must equal the adjusted gross p to the issuer set forth in response to Part C - Question 4.b above. | y the roceeds | |
| | Payment to Officers, | Payments To Others |
| | Directors, & Affiliates | |
| Salaries and fees | | <u> </u> |
| Purchase of real estate | — | □ <u>\$</u> |
| Purchase, rental or leasing and installation of machinery and equipment | - | □ \$ |
| Construction or leasing of plant buildings and facilities | | □ S <u>-0-</u> |
| Acquisition of other businesses (including the value of securities involved in offering that may be used in exchange for the assets or securities of another is | | |
| pursuant to a merger) | | ☐ \$ 0- |
| Repayment of indebtedness | so- | □ \$o- |
| Working capital | s <u>-0-</u> | X \$31,539,643.88 |
| Other (specify): | | _ |
| | \$ <u>-0-</u> | □ \$ <u> -o-</u> |
| Column Totals | s <u>-0-</u> | ☐ \$ |
| Total Payments Listed (column totals added) | I | \$31,539,643.88 |
| D. FEDERAL SI | | |
| The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to | ities and Exchange Commission, upon | |
| signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) | ities and Exchange Commission, upon | |
| signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) QuatRx Pharmaceuticals Company | ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature | written request of its staff, the |
| signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) | ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. | written request of its staff, the |
| signature constitutes an undertaking by the issuer to furnish to the U.S. Secur information furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) QuatRx Pharmaceuticals Company Name of Signer (Print or Type) | ities and Exchange Commission, upon paragraph (b)(2) of Rule 502. Signature Title of Signer (Print or Type) | written request of its staff, the |

 $\mathbb{E}\mathcal{N}\mathcal{D}$

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)